To compare the effects of Polyherbal Unani Formulation with a standard drug in the Management of Uncomplicated Urinary tract infection.

A Clinical study to evaluate the Efficacy of a Unani Formulation in the management of uncomplicated Urinary Tract infection (Waram-E-Aalate Bawl)-Randomized control Trial - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/04/085795

Enrollment

Registered

2025-04-28

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N300- Acute cystitis

Interventions

Intervention1: Powder of Unani Drug-Kabab chini(Cubeba officinalis)2g,along with Sharbat e sandal: 2 capsule of 500mg twice daily orally with Sharbat e sandal 10ml for 15 days Control Intervention1: C

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient willing to participate in the study and sign the informed consent form. 2.Female patients of the reproductive age group between 20-45 years. 3.Presenting with acute following symptoms(Burning micturition,dysuria, frequency and urgency) 4.Diagnose cases of urinalysis showing pus cells (7-10 white blood cells per high-powered field).

Exclusion criteria

Exclusion criteria: 1.Below 20 and 45 years 2.Any signs evoking complicated UTI, pyelonephritis (fever more or equal 38 degree Celsius, back pain,chills and shivers. 3.Concomitant vulvovaginitis. 4.Conditions leading to complicated infections (Renal diseases, urinary tract abnormalities,past urinary surgery, urine catheterization etc) 5.Pregnancy and lactating mother 6.Cardiovascular diseases and any systematic illness. 7.H/o Sexually transmitted diseases 8.Immune compromised pateints

Design outcomes

Primary

Measure	Time frame
1.To assess the safety and efficacy of the proposed Unani Formulation on scientific parameters. 2.To compare the results of Unani Formulation with the standard control in the treatment of uUTI in respect of safety and efficacy. Timepoint: Improvement in signs and symptoms of uUTI patient at 15 days from base line	—

Secondary

Measure	Time frame
To evaluate the effect of Unani polyherbal formulation on quality of the patientTimepoint: Change in urinalysis showing pus cells at 15 days from base line	—

Countries

India

Contacts

Public ContactHUZAIFA FATHIMA P

Ayurvedic and Unani Tibbia college and hospital

draysharaza11@gmail.com9354925031

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026